Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-04-13 00:00:00+00:00 | ABBV | US FDA declines to approve Eli Lilly's bowel disease drug | Adds details
April 13 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined approval for Eli Lilly and Co's LLY.Ndrug to treat a type of chronic inflammatory bowel disease in adults, the company said on Thursday.
The health regulator cited issues related to the proposed manufacturing of the drug, mirikiz... |
2023-04-13 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources | For Immediate Release
Chicago, IL – April 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Ab... |
2023-04-12 00:00:00+00:00 | ABBV | Noteworthy Wednesday Option Activity: KMX, AAL, ABBV | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Carmax Inc. (Symbol: KMX), where a total volume of 41,667 contracts has been traded thus far today, a contract volume which is representative of approximately 4.2 million underlying shares (given that every ... |
2023-04-12 00:00:00+00:00 | ABBV | Top Research Reports for JPMorgan Chase, AbbVie & NextEra Energy | Wednesday, April 12, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and NextEra Energy, Inc. (NEE). These research reports have been hand-picked from t... |
2023-04-12 00:00:00+00:00 | ABBV | See Which Of The Latest 13F Filers Holds AbbVie | At Holdings Channel, we have reviewed the latest batch of the 24 most recent 13F filings for the 03/31/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 16 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... |
2023-04-12 00:00:00+00:00 | ABBV | Why AbbVie (ABBV) Could Beat Earnings Estimates Again | Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry.
When looking at the last two reports, this drugmaker has recorded a strong streak of surpas... |
2023-04-12 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-12 00:00:00+00:00 | ABBV | Why 2023 Could Be a Tough Year for AbbVie Stock | At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. It even has the added bonus of an attractive dividend yield of 3.7%. But there are some risks under the hood that should give investors some second thoughts about owning this pharmaceutical stock.
Here's why this ... |
2023-04-11 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Moves 0.06%: What You Should Know | AbbVie (ABBV) closed at $161.38 in the latest trading session, marking a +0.06% move from the prior day. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 1.92%.
Prior to today's trading, shares of the drugmaker had gained 6.14% over the past month. This has lagged the Medical sector's gain of 6.4% and... |
2023-04-11 00:00:00+00:00 | ABBV | Ex-Dividend Reminder: AbbVie, Abbott Laboratories and Mid-America Apartment Communities | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.48 on 5/1... |
2023-04-11 00:00:00+00:00 | ABBV | 2 Forever Stocks to Buy No Matter What the Market Is Doing | In tough economic times, many companies see their revenue decline. And in good times, these companies may see just the opposite -- revenue takes off. It's fine to include these players in your portfolio. But it's also a great idea to buy companies that generally deliver earnings growth no matter what the market is doin... |
2023-04-10 00:00:00+00:00 | ABBV | Morgan Stanley Maintains AbbVie (ABBV) Overweight Recommendation | Fintel reports that on April 10, 2023, Morgan Stanley maintained coverage of AbbVie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 3.46% Upside
As of April 6, 2023, the average one-year price target for AbbVie is $167.15. The forecasts range from a low of $136.35 to a high of $210.00. The... |
2023-04-10 00:00:00+00:00 | ABBV | AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica | AbbVie ABBV and Johnson & Johnson JNJ announced they would voluntarily withdraw the accelerated approvals granted by the FDA to Imbruvica (ibrutinib) in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) indications. This decision was made in consultation with the FDA.
This decision to voluntarily withdraw two... |
2023-04-10 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-10 00:00:00+00:00 | ABBV | Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | The Invesco Dynamic Pharmaceuticals ETF (PJP) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, a strateg... |
2023-04-07 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-07 00:00:00+00:00 | ABBV | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | Making its debut on 10/09/2013, smart beta exchange traded fund ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted index... |
2023-04-06 00:00:00+00:00 | ABBV | AbbVie plans to pull US accelerated approvals for some blood cancer treatments | Adds details
April 6 (Reuters) - AbbVie Inc ABBV.N intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer, the drugmaker said on Thursday.
The company plans to voluntarily withdraw accelerated approvals of Imbruvica for patients with m... |
2023-04-06 00:00:00+00:00 | ABBV | Unusual Put Option Trade in AbbVie (ABBV) Worth $936.31K | On April 6, 2023 at 10:53:11 ET an unusually large $936.31K block of Put contracts in AbbVie (ABBV) was sold, with a strike price of $160.00 / share, expiring in 71 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.22 sigmas above the mean, placing it in the 99.2... |
2023-04-06 00:00:00+00:00 | ABBV | AbbVie intends to withdraw accelerated approvals of blood cancer drug | April 6 (Reuters) - AbbVie Inc said on Thursday it intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer.
The company said other approved indications for the drug in the U.S. are not affected. (Reporting by Sriparna Roy in Bengaluru; ... |
2023-04-06 00:00:00+00:00 | ABBV | Health Care Sector Update for 04/06/2023: ZIVO, ABBV, PFE, XLV, IBB | Health care stocks were advancing premarket Thursday. The Health Care Select Sector SPDR Fund (XLV) was up 0.27% and the iShares Biotechnology ETF (IBB) was recently unchanged.
Zivo Bioscience (ZIVO) was up more than 4% after saying it has received a $1 million unsecured six-month loan from its Chief Executive Officer ... |
2023-04-06 00:00:00+00:00 | ABBV | Johnson & Johnson (JNJ) Soars 4.5%: Is Further Upside Left in the Stock? | Johnson & Johnson JNJ shares ended the last trading session 4.5% higher at $165.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% gain over the past four weeks.
Share price rose after management announced that J&J’s sub... |
2023-04-05 00:00:00+00:00 | ABBV | Argus Research Downgrades AbbVie (ABBV) | On April 5, 2023, Argus Research downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Hold .
Analyst Price Forecast Suggests 4.61% Upside
As of March 30, 2023, the average one-year price target for AbbVie is $167.15. The forecasts range from a low of $136.35 to a high of $210.00. The average price target represe... |
2023-04-05 00:00:00+00:00 | ABBV | Better Dividend Stock: AbbVie vs. Johnson & Johnson | The pharmaceutical industry is a great place to look for dividend stocks, and AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are among the best. Both drugmakers generally grow their dividends at a good clip, and both are part of the highly exclusive group of Dividend Kings, having raised their payouts for more t... |
2023-04-05 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-05 00:00:00+00:00 | ABBV | Want to Collect Big Dividends Each Month? Buy These 3 Stocks | Dividend growth investing is a strategy that can help you achieve financial independence -- a state in which your monthly passive income is equal to or greater than your monthly expenses. Building a balanced portfolio with dividend income coming in every month is a surefire way to reach financial independence in the lo... |
2023-04-03 00:00:00+00:00 | ABBV | 3 Dividend ETFs to Consider Buying with Your Tax Return | If you’re getting a tax return, there are plenty of ways you can spend it. However, investing in a dividend ETF may be one of the best choices. The top dividend ETFs give you instant diversification to a broad swath of dividend-paying stocks, they pay you passive income on a periodic basis, and you can use these paymen... |
2023-04-03 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-03 00:00:00+00:00 | ABBV | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $160.42, marking a +0.66% move from the previous day. This move outpaced the S&P 500's daily gain of 0.37%. Elsewhere, the Dow gained 0.98%, while the tech-heavy Nasdaq added 0.62%.
Coming into today, shares of the drugmaker had gained 2.12% in the past month. In t... |
2023-04-02 00:00:00+00:00 | ABBV | These 5 High-Yield Dividend Stocks Should Make Me $3,000 in Passive Income This Year | Nearly everyone has to work for their money. But too few put their money to work for them. There are plenty of ways to do it. My favorite method is investing in stocks.
Stocks can make you money in a couple of key ways. Their share prices can appreciate. Some also pay dividends. My portfolio currently includes 12 high-... |
2023-04-01 00:00:00+00:00 | ABBV | Could This Drug News Lift AbbVie's Stock? | Perhaps as much as any industry, pharmaceutical makers must innovate to survive and thrive. That's because the same patents which protect a medicine from biosimilar competition eventually expire, often leading to a precipitous decline in sales.
Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $2... |
2023-03-31 00:00:00+00:00 | ABBV | This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie | AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC).
With an approval from the U.S. Food and Drug Administration looking more like a matter of "when" than "if," it's worth asking the fol... |
2023-03-31 00:00:00+00:00 | ABBV | The Top Healthcare Stocks to Buy With $100 | A common misconception is that you need a lot of money to invest in the stock market. However, even a small amount is enough to start. With the right stocks, a small investment can grow greatly in value. Some growth stocks have the potential to deliver massive returns as long as you have a little patience and a reasona... |
2023-03-31 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-30 00:00:00+00:00 | ABBV | PFE vs. ABBV: Which Pharmaceutical Stock is Better? | In this piece, I used TipRanks' comparison tool to evaluate two pharmaceutical stocks, Pfizer Inc. (NYSE:PFE) and AbbVie Inc. (NYSE:ABBV), to determine which is better. Pfizer has plummeted more than 20% year-to-date, while AbbVie has held up much better, with a decline of about 2%. A closer look at both companies reve... |
2023-03-30 00:00:00+00:00 | ABBV | IVW, CVX, ABBV, MRK: Large Inflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $172.1 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 466,150,000 to... |
2023-03-30 00:00:00+00:00 | ABBV | 2 High-Yielding Dividend Investments to Buy for the Long Haul | Want some safe stocks you can hold in your portfolio and not worry about, and that also provide high yields? Two companies which fit the bill and you should consider loading up on now are AbbVie (NYSE: ABBV) and Coca-Cola (NYSE: KO). These are among the best dividend stocks you can buy for the long haul.
1. Coca-Cola
O... |
2023-03-29 00:00:00+00:00 | ABBV | Investing Your Tax Return? Check Out This 11.8%-Yielding ETF | Tax season is upon us once again. If you are getting a tax return, why not consider investing in a dividend ETF instead of spending it on a new gadget or a night out on the town?
Using your tax return to buy a high-yielding dividend ETF can help you to jump-start your own dividend portfolio. Investing in a dividend ETF... |
2023-03-29 00:00:00+00:00 | ABBV | Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie | Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. In fact, in 2022 these dynamic biotech stocks climbed by percentages in the double digits, and for good reason. People need medicines no matter what the market is doing -- and this helps healthcare companies maintain earnin... |
2023-03-29 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-29 00:00:00+00:00 | ABBV | Better Growth Stock: AbbVie vs. Pfizer | AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. Both players are going to face some headwinds over the next couple of years as the income from their cash cow medicines sharply erodes. Beyond that, however, both have big plans to k... |
2023-03-28 00:00:00+00:00 | ABBV | DIV ETF Yields 7.3% and Pays Monthly. Here are the Pros and Cons | With a monthly dividend payout and a yield that beats inflation, the Global X SuperDividend ETF (NYSEARCA:DIV) is a tempting choice for dividend investors. However, there are several pros and cons that investors should weigh when it comes to this high-yield ETF.
What Does the DIV ETF Do?
DIV is another one of Global ... |
2023-03-28 00:00:00+00:00 | ABBV | ABBV December 2025 Options Begin Trading | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 2025 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 997 days until expiration the newly trading contracts represent a possible opportunity for selle... |
2023-03-28 00:00:00+00:00 | ABBV | 2 Relatively Safe Dividend Stocks You Won't Regret Owning | Most of us spend a lot of mental energy on trying to avoid bumbling into fresh regrets, especially when it comes to our investments. While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their his... |
2023-03-28 00:00:00+00:00 | ABBV | This Is the Best Dividend ETF You Can Buy | The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the fund's largest weighted position. SCHD is great because it can offer a solid yield, strong dividend growth, and share ap... |
2023-03-27 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day. This change lagged the S&P 500's daily gain of 0.17%. Elsewhere, the Dow gained 0.6%, while the tech-heavy Nasdaq added 0.67%.
Heading into today, shares of the drugmaker had gained 3.48% over the past month, out... |
2023-03-27 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-27 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly | For Immediate Release
Chicago, IL – March 27, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sanofi SNY, Regeneron REGN, ... |
2023-03-27 00:00:00+00:00 | ABBV | BioNTech Is Ripe For A Rebound In 2023 | BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE: PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in. While COVID sales have slowed, this company is not dependent on COVID for its bread and butt... |
2023-03-27 00:00:00+00:00 | ABBV | Amgen-Sanofi patent case divides makers of antibody drugs | By Patrick Wingrove
March 27 (Reuters) - Amgen Inc's AMGN.O battle with Sanofi SASY.PA and Regeneron REGN.O at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.
In the dispute ... |
2023-03-25 00:00:00+00:00 | ABBV | Better Buy: AbbVie vs. Johnson & Johnson | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. They outperformed the S&P 500 index.
These pharmaceutical giants defied the bear market as investors favored the safety of healthcare. After all, even in a difficult economy, people generally still need their medicat... |
2023-03-24 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-24 00:00:00+00:00 | ABBV | Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL | This week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a pivotal study for yet another new indication, chronic obstructive pulmonary disease (COPD).The FDA declined to approve AbbVie’s ABBV Parkinson’s disease (PD) therapy, ABBV-951. Roche RHHBY entered into a deal with Eli Lilly... |
2023-03-24 00:00:00+00:00 | ABBV | 3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence | If you're not using artificial intelligence (AI) in your investing process, you're missing out on something that could empower your decision-making unlike anything ever before. Biotech and pharma investing is quite complex, and AI is a great way to slash through the complexity to make it more understandable. And you do... |
2023-03-24 00:00:00+00:00 | ABBV | Notable Friday Option Activity: CBL, ABBV, ISRG | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CBL & Associates Properties Inc (Symbol: CBL), where a total volume of 1,070 contracts has been traded thus far today, a contract volume which is representative of approximately 107,000 underlying share... |
2023-03-24 00:00:00+00:00 | ABBV | AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs | AbbVie ABBV announced multiple clinical updates pertaining to clinical studies evaluating its blockbuster drugs Skyrizi and Rinvoq for expanded use.
Management announced topline data from the phase III INSPIRE study, which evaluated Skyrizi (risankizumab) as an induction therapy in adult patients with moderately to sev... |
2023-03-23 00:00:00+00:00 | ABBV | 2 High-Yield Dividend Stocks You Won't Regret Buying Right Now | High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. That said, these highly coveted income plays can also be fraught with risk, so it's important for investors to understand the threats and opportunities of the business behind the yield.
Which high-yield dividend stocks are ... |
2023-03-23 00:00:00+00:00 | ABBV | AbbVie: Phase 3 Induction Study With Risankizumab Meets Endpoints | (RTTNews) - AbbVie (ABBV) reported positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. In the study, 20.3% of patient... |
2023-03-23 00:00:00+00:00 | ABBV | Use These 3 Strategies to Make $1,000 in Passive Income Per Year | Passive income is a holy grail for many investors, but it's a lot easier to want it than it is to make enough of it from your holdings. Buying shares of any old dividend stock simply won't do; you need a strategy that's right for your goals and your means.
So, let's explore three strategies that can help you invest for... |
2023-03-23 00:00:00+00:00 | ABBV | 2 Reasons to Buy AbbVie, and 1 Reason to Sell | AbbVie (NYSE: ABBV) wowed investors last year when it outperformed the S&P 500 index. Shares of the pharmaceutical company climbed 19%, while the benchmark fell by as much.
Since the start of the year, though, AbbVie shares have lost momentum. Why? The company's blockbuster immunology drug, Humira, is facing competitio... |
2023-03-22 00:00:00+00:00 | ABBV | US FDA declines to approve AbbVie's Parkinson's disease therapy | Adds background
March 22 (Reuters) - AbbVie Inc ABBV.N said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults.
The U.S. health regulator has sought additional information about the delivery pump, which is part of the marketing application, the drugmake... |
2023-03-22 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-22 00:00:00+00:00 | ABBV | AbbVie: FDA Requests Additional Information Related To NDA Review Of ABBV-951 | (RTTNews) - AbbVie (ABBV) announced it received a Complete Response Letter from the FDA for the New Drug Application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson's disease. The FDA requested additional information about the device as part of the NDA review. The company plans to... |
2023-03-22 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned +3.1%, compared to the Zacks S&P 500 composite's +0.3% change. Dur... |
2023-03-22 00:00:00+00:00 | ABBV | Here's What is Driving Amgen (AMGN) Stock's Outperformance | Amgen AMGN is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology and neuroscience markets.
Thousand Oaks, CA-based Amgen also has a promising pipeline of cancer drugs. It has one of the stro... |
2023-03-21 00:00:00+00:00 | ABBV | 5 Dividend Aristocrats Where Analysts See Capital Gains | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-03-20 00:00:00+00:00 | ABBV | Should You Buy The Botox Maker Over Johnson & Johnson Stock? | We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Although AbbVie is trading at 4.8x trailing revenues compared to 4.2x for J&J, this gap in valuation looks justified, given the former’s superior revenue g... |
2023-03-20 00:00:00+00:00 | ABBV | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day. This move outpaced the S&P 500's daily gain of 0.89%. Meanwhile, the Dow gained 1.2%, and the Nasdaq, a tech-heavy index, lost 0.68%.
Heading into today, shares of the drugmaker had gained 1.92% over the past mo... |
2023-03-20 00:00:00+00:00 | ABBV | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | The Invesco Dynamic Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among instit... |
2023-03-20 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-20 00:00:00+00:00 | ABBV | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First Trust Morningstar Dividend Leaders ETF (FDL) is a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $4.90 billion, making it one of ... |
2023-03-17 00:00:00+00:00 | ABBV | After Hours Most Active for Mar 17, 2023 : LUMN, F, HBI, ABBV, IBM, PEB, INTC, GOOG, AAPL, HBAN, AMZN, VSAT | The NASDAQ 100 After Hours Indicator is down -5.75 to 12,514.13. The total After hours volume is currently 510,996,400 shares traded.
The following are the most active stocks for the after hours session:
Lumen Technologies, Inc. (LUMN) is -0.02 at $2.46, with 101,594,315 shares traded. LUMN's current last sale is 41%... |
2023-03-17 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-16 00:00:00+00:00 | ABBV | 2 Growth Stocks to Buy Before the Bull Market Arrives | Timing the market is a risky strategy. If you wait too long, you can miss the rally when it inevitably comes. Investors react quickly to news, and so if you've found a good stock at a decent valuation, you shouldn't wait to buy it. Provided you're willing to buy and hold for years, now may be a good time to buy stocks ... |
2023-03-15 00:00:00+00:00 | ABBV | U.S. issues initial Medicare drug price negotiation guidance | By Ahmed Aboulenein and Michael Erman
WASHINGTON, March 15 (Reuters) - The U.S. government will select the Medicare program's 10 costliest prescription medicines based on gross spending for negotiating price cuts that will go into effect in 2026, the U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesd... |
2023-03-15 00:00:00+00:00 | ABBV | US to impose inflation fines on first set of drugs, lowering costs | By Ahmed Aboulenein
WASHINGTON, March 15 (Reuters) - The U.S. government said on Wednesday it would subject 27 drugs to inflation penalties, a move that will reduce out-of-pocket costs for Medicare recipients by $2 to as much as $390 per average dose.
"Starting on April 1, Medicare beneficiaries will pay lower coinsura... |
2023-03-15 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-14 00:00:00+00:00 | ABBV | UPRO, ABBV, LLY, BAC: Large Outflows Detected at ETF | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $75.7 million dollar outflow -- that's a 3.7% decrease week over week (from 64,200,000 to 61,850,000). Among th... |
2023-03-14 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, NextEra Energy, ConocoPhillips, Canadian Pacific Railway and Intercontinental Exchange | For Immediate Release
Chicago, IL – March 14, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, NextEra En... |
2023-03-14 00:00:00+00:00 | ABBV | 5 Forever Dividend Stocks | All five of these dividend stocks are of the highest quality and they have a long track record of growing their dividend payouts. Two of the stocks are Dividend Kings and two have a AAA credit rating, one of those being Microsoft (NASDAQ: MSFT).
Check out this short video to learn more, consider subscribing to the chan... |
2023-03-14 00:00:00+00:00 | ABBV | Diversify Your Income with These 2 High-Yielding Dividend ETFs | Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and industries to minimize volatility's impact. While one segment may take a hit, another one may improve or take less of a hit. In a nutshell, don't put all of your eggs int... |
2023-03-13 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gains As Market Dips: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $151.95, moving +1.5% from the previous trading session. This change outpaced the S&P 500's 0.15% loss on the day. Elsewhere, the Dow lost 0.28%, while the tech-heavy Nasdaq added 3.16%.
Heading into today, shares of the drugmaker had lost 1.54% over the past month, o... |
2023-03-13 00:00:00+00:00 | ABBV | Top Research Reports for AbbVie, NextEra Energy & ConocoPhillips | Monday, March 13, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NextEra Energy, Inc. (NEE) and ConocoPhillips (COP). These research reports have been hand-picked from the roughl... |
2023-03-13 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-13 00:00:00+00:00 | ABBV | Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation | By Michael Erman, Patrick Wingrove and Ahmed Aboulenein
NEW YORK/WASHINGTON, March 13 (Reuters) - The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S. price negotiations for 2026... |
2023-03-13 00:00:00+00:00 | ABBV | Galderma posts 2022 revenue growth ahead of planned IPO | By Emma-Victoria Farr
FRANKFURT, March 13 (Reuters) - Swiss dermatology company Galderma posted $3.8 billion in net sales during 2022, up 13.9% on 2021 on a constant currency basis, driven by growth in its injectable aesthetics and dermatological skincare units.
The results come ahead of a possible initial public offer... |
2023-03-11 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-11 00:00:00+00:00 | ABBV | 3 No-Brainer Dividend Stocks to Buy in March | Some decisions are painstakingly difficult. Others are downright easy. Choosing from the thousands of dividend stocks on the market can fall into the former category. But it doesn't have to.
Three Fool.com contributors selected dividend stocks they believe are no-brainer picks to buy in March. Here's why they chose Abb... |
2023-03-10 00:00:00+00:00 | ABBV | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -0.9% over the past month versus the Zacks S&P 500 composite's -3.8% chan... |
2023-03-10 00:00:00+00:00 | ABBV | U.S. FDA approves Pfizer's nasal spray for migraine | Adds background
March 10 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's PFE.N nasal spray for migraine, giving patients access to a potentially fast-acting option to treat their headaches.
The drug Zavzpret, also known as zavegepant, was approved for the treatment of acute migra... |
2023-03-10 00:00:00+00:00 | ABBV | Zacks Investment Ideas feature highlights: Coca-Cola Company, AbbVie and Exxon Mobil | For Immediate Release
Chicago, IL – March 10, 2023 – Today, Zacks Investment Ideas feature highlights Coca-Cola Company KO, AbbVie ABBV and Exxon Mobil XOM.
Reap Monthly Income with This 3-Stock Combo
While the majority of stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get... |
2023-03-09 00:00:00+00:00 | ABBV | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | The WisdomTree U.S. High Dividend ETF (DHS) made its debut on 06/16/2006, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, ... |
2023-03-09 00:00:00+00:00 | ABBV | Surprising Analyst 12-Month Target For HUSV | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Horizon Managed Vol... |
2023-03-09 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV - Partha Mohanram | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-03-09 00:00:00+00:00 | ABBV | Is It Too Late to Buy AbbVie Stock? | AbbVie (NYSE: ABBV) has shown itself to be a great long-term investment. The drugmaker's shares have climbed about 300% over the past decade. And earnings have soared, thanks to the company's blockbuster immunology drug Humira.
But things are changing at AbbVie. Humira already has been facing competition internationall... |
2023-03-09 00:00:00+00:00 | ABBV | 3 High-Yield Dividend Stocks to Buy Before the Next Bull Rally | The current bear market has been brutal for investors of all kinds. Even shares of well-established businesses that are components of the S&P 500 index haven't escaped the beatings. The benchmark index is down around 17% from the peak it reached more than a year ago.
The market's dismal performance since the end of 202... |
2023-03-09 00:00:00+00:00 | ABBV | 3 Surefire Stocks That Are Screaming Buys in March | For long-term investors, growth stocks are a superior option in a volatile market. Long-term investors can afford to be far less concerned with short-term fluctuations in stock prices. Growth stocks generally take time to show their full potential, so they tend to be good options for patient investors with a high appet... |
2023-03-08 00:00:00+00:00 | ABBV | Noteworthy Wednesday Option Activity: ANET, ABBV, ASAN | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Arista Networks Inc (Symbol: ANET), where a total volume of 10,002 contracts has been traded thus far today, a contract volume which is representative of approximately 1.0 million underlying shares (giv... |
2023-03-07 00:00:00+00:00 | ABBV | The Stock That Tripled in a Day...And May Not Be Done | Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. The news flow was light, the trading pattern sideways and volume virtually nonexistent.
Things changed in dramatic fashion last week.
On February 28th, the U.S. Food and Drug Administration (FDA) approved ... |
2023-03-07 00:00:00+00:00 | ABBV | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | The WisdomTree U.S. High Dividend ETF (DHS) was launched on 06/16/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.48 billion, making it one of the average siz... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.